2021-11-29 07:32:30 BCLI BrainStorm
11/29/21 11/2907:32 11/29/2107:32 | BrainStorm announces presentation of new analyses from Phase 3 trial of NurOwnBrainStorm Cell Therapeutics announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium. The presentation, which will be delivered Tomorrow, showed that although the Phase 3 trial did not reach statistical significance on the primary and secondary endpoints, pre-specified and post hoc analyses leveraging different methods of exploring the heterogeneity of baseline disease in the trial, revealed the potential for a meaningful treatment effect across endpoints when focusing on a subset of participants with less severe disease at baseline. Additional key findings from the presentation included: The observed potential treatment effect of NurOwn on ALS disease progression in participants with less severe disease was protected by randomization; The Phase 3 trial of NurOwn in ALS included a higher percentage of participants with advanced ALS at baseline compared to other trials, resulting in a lower baseline mean; In the subgroup of participants that are predicted by the ENCALS model to have long to very long survival, NurOwn treated participants had a greater percentage of responders compared to placebo; In the pre-specified subgroup of participants with ALSFRS-R greater than or equal to 35 at baseline, NurOwn had a greater percentage of responder compared to placebo; and Analyses that focus both on baseline ALSFRS-R and ENCALS model categories suggest that efficacy measurements are impacted in participants with more severe disease. "These compelling analyses add to the positive momentum behind our ALS program, and we were pleased to have the opportunity to share them with the clinical community at this year's ALS ONE Research Symposium," said Stacy Lindborg, PhD, Executive Vice President and Chief Development Officer, Brainstorm Cell Therapeutics. "We are very encouraged by the observation that there appears to be a meaningful treatment effect in patients with less severe disease at baseline that is consistent when using baseline ALSFRS-R scores and the ENCALS model which incorporates additional important disease characteristics that have been shown to be predictive of survival time. We believe this is an important finding, especially since this effect was protected by randomization. Looking ahead, we are eager to share additional analyses from our Phase 3 trial with the clinical community through a peer reviewed publication and remain committed to pursuing the best and most expeditious path forward to bring NurOwn to patients with ALS." |
|
---|
Recommendations
|
Forterra plc price target lowered to 300 GBp from 340 GBp at Deutsche Bank »
15:34 05/25/22 05/2515:34 05/25/2215:34
FTTRF
Forterra plc
Deutsche Bank analyst Jon… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
BNP Paribas price target raised to EUR 66 from EUR 64 at Deutsche Bank »
15:33 05/25/22 05/2515:33 05/25/2215:33
BNPQY
BNP Paribas
Deutsche Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
AB InBev price target raised to EUR 74 from EUR 67 at Deutsche Bank »
15:32 05/25/22 05/2515:32 05/25/2215:32
BUD
AB InBev
Deutsche Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Uber participates in a conference call with Mizuho »
15:27 05/25/22 05/2515:27 05/25/2215:27
UBER
Uber
Conference call with… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Lem Holding price target lowered to CHF 2,050 from CHF 2,320 at Credit Suisse »
15:22 05/25/22 05/2515:22 05/25/2215:22
LMHDF
Lem Holding
Credit Suisse analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Adevinta price target lowered to NOK 123 from NOK 140 at Credit Suisse »
15:21 05/25/22 05/2515:21 05/25/2215:21
ADEVF
Adevinta
Credit Suisse analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Societe Generale price target raised to EUR 32 from EUR 29 at RBC Capital »
15:20 05/25/22 05/2515:20 05/25/2215:20
SCGLY
Societe Generale
RBC Capital analyst Anke… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Alliance Global says Motus GI EU data bodes well for U.S. outpatient study »
15:18 05/25/22 05/2515:18 05/25/2215:18
MOTS
Motus GI Holdings
After Motus GI announced… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
|
NASDAQ market internals summary »
15:17 05/25/22 05/2515:17 05/25/2215:17
$NSD
NASDAQ Market Internals
Volume is above average… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
| Volume is above average… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
eXp World Holdings management to meet virtually with Stephens »
15:11 05/25/22 05/2515:11 05/25/2215:11
EXPI
eXp World Holdings
Virtual Meeting to be… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Compass Group price target raised to 1,500 GBp from 1,340 GBp at RBC Capital »
15:10 05/25/22 05/2515:10 05/25/2215:10
CMPGY
Compass Group
RBC Capital analyst Karl… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Donaldson raises quarterly dividend to 23c from 22c per share »
15:09 05/25/22 05/2515:09 05/25/2215:09
DCI
Donaldson
The dividend is payable… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Richemont price target lowered to CHF 142 from CHF 158 at Barclays »
15:06 05/25/22 05/2515:06 05/25/2215:06
CFRUY
Richemont
Barclays analyst Carole… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Glencore price target raised to 770 GBp from 730 GBp at Barclays »
15:05 05/25/22 05/2515:05 05/25/2215:05
GLNCY
Glencore
Barclays analyst Ian… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
DSM price target lowered to EUR 188 from EUR 189 at Barclays »
15:05 05/25/22 05/2515:05 05/25/2215:05
RDSMY
DSM
Barclays analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
BHP Group price target lowered to 2,400 GBp from 2,700 GBp at Barclays »
15:04 05/25/22 05/2515:04 05/25/2215:04
BHP
BHP Group
Barclays analyst Amos… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Adevinta price target lowered to NOK 100 from NOK 115 at Barclays »
15:03 05/25/22 05/2515:03 05/25/2215:03
ADEVF
Adevinta
Barclays analyst Andrew… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Acciona price target raised to EUR 180 from EUR 152 at Barclays »
15:03 05/25/22 05/2515:03 05/25/2215:03
ACXIF
Acciona
Barclays analyst Jose… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Columbus McKinnon downgraded to Hold at Craig-Hallum on lack of catalysts »
14:52 05/25/22 05/2514:52 05/25/2214:52
CMCO
Columbus McKinnon
Craig-Hallum analyst Greg… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
BASF price target lowered to EUR 62 from EUR 64 at Morgan Stanley »
14:51 05/25/22 05/2514:51 05/25/2214:51
BASFY
BASF
Morgan Stanley analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Aurubis price target lowered to EUR 87 from EUR 95 at Morgan Stanley »
14:51 05/25/22 05/2514:51 05/25/2214:51
AIAGY
Aurubis
Morgan Stanley analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Prosus price target lowered to EUR 90 from EUR 110 at Citi »
14:50 05/25/22 05/2514:50 05/25/2214:50
PROSY
Prosus
Citi analyst Catherine… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
EOCL award watershed moment for BlackSky, GIS industry, says Benchmark »
14:50 05/25/22 05/2514:50 05/25/2214:50
BKSY
BlackSky
Planet Labs
Maxar Technologies
Benchmark analyst Josh… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Columbus McKinnon downgraded to Hold from Buy at Craig-Hallum »
14:49 05/25/22 05/2514:49 05/25/2214:49
CMCO
Columbus McKinnon
Craig-Hallum analyst Greg… Story temporarily locked. ShowHide Related Items >><<
|